Substance use disorders occur at 2 to 3 times the rate in adults with diabetes compared with the general population and substantially worsen self-management outcomes. The relationship runs in multiple directions: pre-existing substance use disorders increase diabetes risk through metabolic and behavioral pathways; established diabetes increases substance use risk through chronic disease burden, depression, chronic pain, and reduced quality of life. Each major class of substances has distinct diabetes-relevant effects: alcohol causes delayed hypoglycemia, opioids modestly raise glucose and impair hypoglycemia awareness, stimulants cause acute hyperglycemia and risk-taking. This guide covers the major substance categories, their specific diabetes interactions, and the treatment approaches that work for dual diagnoses.
The Scope of the Problem
| Substance | Use disorder prevalence in diabetes | Notes |
|---|---|---|
| Alcohol | 15-20% | Most common; delayed hypoglycemia risk |
| Tobacco | 20-25% | Major cardiovascular risk multiplier |
| Cannabis | 5-10% | Increasing with legalization |
| Opioids | 3-6% | Often starts with neuropathic pain treatment |
| Stimulants (meth, cocaine) | 1-3% | Dramatic glucose effects |
| Benzodiazepines | 2-4% | Risk masks hypoglycemia |
| Hallucinogens | <1% | Less direct glucose impact |
Alcohol — The Major Concern
- Alcohol inhibits hepatic gluconeogenesis — the liver cannot release stored glucose when blood sugar drops.
- This causes delayed hypoglycemia, often 8 to 12 hours after drinking.
- Risk is greatest in adults on insulin or sulfonylureas, when drinking on empty stomach, and during binge drinking.
- Carbohydrate content varies enormously: beer 10-20 g per 12 oz; dry wine 3-4 g per 5 oz; sweet cocktails 20-30 g.
- Spirits are essentially zero-carb but disrupt glucose regulation.
- Chronic heavy alcohol use damages the pancreas — can cause secondary type 3c diabetes.
- Alcohol also impairs hypoglycemia awareness and judgment about treating lows.
Safer Alcohol Use Guidelines
- ADA recommendations: up to 1 drink/day for women, 2 drinks/day for men if drinking.
- Always drink with food.
- Check glucose more frequently around drinking — before bed, overnight, and next morning.
- Avoid drinking on empty stomach.
- Have backup carbohydrate available during and after drinking.
- Wear medical ID — hypoglycemia can be mistaken for intoxication.
- Never rely on alcohol as a meal replacement.
- For CGM users: set lower alert thresholds at night after drinking.
Opioid Use Disorder
- Often starts with prescription opioids for diabetic peripheral neuropathy pain.
- Chronic opioid use raises fasting glucose modestly and worsens insulin sensitivity.
- Opioids cause severe constipation — compounds diabetic gastroparesis.
- Drowsiness reduces self-management attention.
- Impaired hypoglycemia awareness — sedation masks symptoms.
- Risk of overdose with insulin overdose; opioid overdose can cause hypoglycemia secondarily.
- Better neuropathic pain treatments exist: duloxetine, gabapentin, pregabalin, topical capsaicin or lidocaine.
Stimulant Use Disorder
- Methamphetamine and cocaine cause substantial acute hyperglycemia through catecholamine surge.
- Glucose can spike 100 to 200 mg/dL during acute use.
- Suppressed appetite leads to skipped meals and unpredictable dosing patterns.
- Dehydration risk is high; can precipitate DKA in T1D.
- Cardiovascular effects compound diabetes-related CV risk.
- Chronic use elevates diabetes incidence through behavioral and possibly direct beta-cell pathways.
- Hyperthermia from MDMA/methamphetamine can affect insulin pump function.
Cannabis Use Considerations
- Effects on glucose are mixed and unclear.
- Some studies show modest improvements in insulin sensitivity in users; others show worsening.
- Cannabis-induced “munchies” can disrupt meal planning and insulin dosing.
- Cannabinoid hyperemesis syndrome causes severe vomiting and can complicate diabetes care.
- Drug interactions with diabetes medications are minor.
- Cannabis use disorder affects 5-10% of adults with diabetes; increasing with legalization.
- Edibles have unpredictable absorption and timing.
Tobacco Use
- Adults with diabetes who smoke have 2× cardiovascular mortality compared with non-smoking adults with diabetes.
- Smoking directly elevates fasting glucose and worsens insulin sensitivity.
- Worsens diabetic complications: retinopathy, neuropathy, nephropathy, foot ulcers.
- Smoking cessation produces modest weight gain (3-5 kg average) but cardiovascular benefit outweighs.
- FDA-approved cessation aids: nicotine replacement (patches, gum, lozenges), bupropion, varenicline.
- Bupropion has antidepressant effect and is weight-neutral.
- E-cigarettes/vaping: less harmful than smoking but not harmless; long-term effects unclear.
Medications for Addiction Treatment (MAT)
| Medication | For | Glucose effect |
|---|---|---|
| Buprenorphine (Suboxone) | Opioid use disorder | Minimal direct effect |
| Methadone | Opioid use disorder | Modest weight gain over time |
| Naltrexone (oral or injection) | Opioid or alcohol use disorder | Minimal direct effect; supports weight management |
| Acamprosate (Campral) | Alcohol use disorder | Minimal direct effect |
| Disulfiram (Antabuse) | Alcohol deterrent | Minimal; aversion-based |
| Varenicline (Chantix) | Tobacco cessation | Minimal direct effect |
| Bupropion (Wellbutrin) | Tobacco cessation; depression | Weight-neutral |
| Nicotine replacement | Tobacco cessation | Minimal |
Treatment Approaches
- Integrated dual diagnosis treatment: addresses substance use and mental health together; best for complex cases.
- Medication-assisted treatment (MAT): buprenorphine, methadone, naltrexone for opioid use disorder; naltrexone, acamprosate for alcohol use disorder.
- Cognitive behavioral therapy (CBT): addresses substance use triggers and coping skills.
- Motivational interviewing: builds intrinsic motivation for change.
- 12-step programs: AA, NA, dual recovery groups.
- Contingency management: incentive-based behavioral treatment with strong evidence.
- Inpatient/residential treatment: for severe substance use disorder with medical complications.
Diabetes Care Coordination
- Disclose substance use to the diabetes care team — without judgment.
- Endocrinologists can adjust regimens for substance use patterns.
- Pharmacist coordination catches drug interactions.
- SAMHSA National Helpline (1-800-662-4357) for treatment referrals.
- Some endocrinology clinics embed substance use screening (NIDA Quick Screen).
- Recovery-oriented diabetes care recognizes that early recovery may not allow perfect glucose control.
Coexisting Conditions
- Depression coexists in 50% of substance use disorders.
- Anxiety disorders coexist in 30-50%.
- PTSD coexists particularly in alcohol and opioid use disorders.
- Bipolar disorder coexists in 30% — see our bipolar and diabetes guide.
- Eating disorders can coexist.
- The treatment plan needs to address all conditions concurrently.
Practical Strategies
- If drinking, follow ADA moderate-use guidelines and never drink on empty stomach.
- For neuropathic pain, try duloxetine, gabapentin, or pregabalin before opioids.
- Smoking cessation is one of the highest-yield diabetes interventions available.
- CGMs are particularly valuable for adults with substance use patterns that disrupt self-monitoring.
- Wear medical ID; emergency contacts informed.
- Connect with support groups for both diabetes and substance use.
- Tell prescribers about all substance use to avoid dangerous interactions.
When to Seek Professional Help
- Cannot reduce or stop substance use despite trying.
- Substance use interferes with diabetes self-management.
- Hypoglycemia episodes related to substance use.
- Cravings dominate daily thought.
- Substance use causing relationship, work, or legal problems.
- SAMHSA National Helpline: 1-800-662-4357 (24/7, confidential, free).
- SAMHSA Treatment Locator: findtreatment.samhsa.gov.
The Bottom Line
Substance use disorders occur at 2 to 3 times the rate in adults with diabetes compared with the general population and substantially worsen self-management outcomes. Alcohol use disorder is the most common comorbid SUD and the most diabetes-relevant — alcohol inhibits hepatic gluconeogenesis and causes delayed hypoglycemia (often 8 to 12 hours after drinking) in adults on insulin or sulfonylureas. Moderate drinking with food is generally acceptable; binge drinking and drinking on empty stomach are dangerous. Opioid use disorder often starts with prescription opioids for diabetic neuropathy pain — better alternatives exist (duloxetine, gabapentin, pregabalin, topical agents). Stimulants cause acute hyperglycemia and dangerous risk-taking. Tobacco is a major cardiovascular risk multiplier — cessation is among the highest-yield diabetes interventions. Medications for addiction treatment (buprenorphine, methadone, naltrexone, varenicline, acamprosate) generally have minimal glucose effects. Integrated dual diagnosis treatment, MAT, CBT, and support groups all have evidence. SAMHSA National Helpline (1-800-662-4357) provides 24/7 confidential treatment referrals. Disclosing substance use to the diabetes care team allows regimen adjustment without judgment. See our depression and diabetes guide for context on the commonly coexisting depression.
